口服避孕药的血栓和血管并发症
Stephen Windisch1, William H Frishman
1From the Departments of Medicine and Cardiology, New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiology in review
|January 17, 2024
概括
口服避孕药是流行的可逆避孕方法. 只有孕激素的药丸更安全,与组合药丸相比,降低了血栓和高血压的风险.
科学领域:
- 生殖健康 生殖健康
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 口服避孕药 (OCP) 是广泛使用的可逆避孕药.
- 有两种主要类型:组合性OCPs (雌激素和孕) 和仅含孕激素的药丸 (POPs).
- 典型的使用故障率为两种类型的7.2%至9%.
研究的目的:
- 审查口服避孕药的安全性概况.
- 为了比较OCP类型之间的血栓和血管并发症风险.
- 突出OCP使用的禁忌和危险因素.
主要方法:
- 关于口服避孕药安全性和并发症的文献综述.
- 与OCPs相关的血栓和血管风险的分析.
- 参考美国疾病预防控制中心 (CDC) 关于使用避孕药的医疗资格标准.
主要成果:
- OCP与血压升高和血栓形成风险有关.
- 这些风险在年轻,健康的个体中是最小的.
- 只有孕激素的药丸在这些并发症方面具有更安全的概况.
结论:
- 对于担心血管并发症的患者,建议服用仅含孕激素的药片.
- 患有高血压,血栓形成史或风险因素的患者需要仔细考虑使用OCP.
- 疾病预防控制中心 (CDC) 提供了关于各种疾病适用避孕药的最新指南.
相关概念视频
Disorders of Hemostasis
918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K


